Production (Stage)
GT Biopharma, Inc.
GTBP
$3.18
$0.144.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.13% | -73.25% | -20.84% | 22.68% | 38.51% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 88.74% | 82.37% | 97.07% | -99.00% | -127.12% |
| Change in Net Operating Assets | 61.11% | -56.11% | -99.45% | -145.55% | 157.62% |
| Cash from Operations | -8.25% | -45.77% | -12.43% | 2.88% | 21.68% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -21.52% | 741.76% | 166.39% | 375.65% | 517.01% |
| Cash from Investing | -21.52% | 741.76% | 166.39% | 375.65% | 517.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -52.52% | -52.52% | -52.52% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -52.52% | -52.51% | -52.51% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 634.74% | 164.55% | 2,010.93% | 350.17% | 98.19% |